博九娱乐网

Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for the treatment of acne, impetigo, and other skin conditions in the United States, Germany, and Israel. Its lead product candidates include FMX101, a novel topical foam formulation which has completed a dose-ranging Phase II clinical trial for the treatment…More of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by methicillin-resistant staphylococcus aureus.